Voronoi, Inc.
KOSDAQ-listed drug developer using its VORONOMICS AI platform to create targeted therapies for lung and breast cancer for licensing out.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2015 and listed on KOSDAQ in 2022, Voronoi is a drug development company focused on early-stage clinical development (Phase 1-2). It develops precision kinase-targeted therapies for cancers such as lung and breast cancer, discovering candidates through its proprietary AI platform VORONOMICS® along with its medicinal chemistry institute, bio institute, animal testing center, and AI institute. The company does not manufacture finished drug products; instead it conducts early clinical trials on its own candidates to verify efficacy in humans and then pursues global out-licensing (License-Out).
Clinical trials
data.go.kr2 MFDS clinical trial authorisations · 2019–2023 (Phase 1 2)
- Phase 1VRN110755 캡슐2023-10-26
11 trial sites
- Phase 1VN100722019-08-13
5 trial sites
R&D and key agreements
Source: DART corporate disclosureKinase 정밀표적치료제 파이프라인(세부 물질명 원문 미기재) · 폐암, 유방암 등 항암 · 초기임상(1~2상) 직접수행 후 기술이전 · Developed using proprietary AI platform VORONOMICS®
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition